Adicet Bio Appoints Dr Blake Aftab as Vice President of Research streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Columbus CEO
Dr. Joshua Joseph, Ohio State University Wexner Medical Center: Pathway to Population Health award, Columbus CEO Healthcare Achievement 2021
Dr. Joshua Joseph remembers the day he realized he wanted to study medicine.
It was the day his grandmother went to the hospital clenching her chest she had type II diabetes, and she suffered from a heart attack. She came home, but would later return to St. Anthony’s, known today as Ohio State University Hospital East. That time, she wouldn’t return home to the family on the Near East Side of Columbus.
Stay up to date with the region’s dynamic business. Subscribe to
SlowMo Therapy Offers Freedom and Peace From Paranoia medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
(0)
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications
Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments
Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline
Company to host conference call today at 4:30 PM ET
ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) f